Feedback Share Discussion Threads

[ducatiman] 11/7/2023 11:09

LR2 must be shorting iqai

[lr2] 10/7/2023 08:47

And shares in IQAI have gone from 14.75p to 2.75p in less than 3 years - at least FDBK has some cash.

[ydderf] 10/7/2023 08:23

LR2, I hope it is a comfort to you, raising all that cash and issuing zillions of shares (the only reason market cap has increased, but even so, a lot less than money raised, most would appear to have been sent to money heaven).

I suggest a better indication of success is the share price, anyone buying FDBK in early 2018 would have lost 80% of their investment by today compared with IQAI where they would have retained nearly all of their investment. Investors now need a £5.70 Feedback share price just to break even.

Your loyalty to TO is admirable and impressive, but will butter no parsnips sadly

[lr2] 07/7/2023 09:40

FDBK mcap £13 mil, IQAI mcap £5 mil.

Wouldn't your time be better spent trying to add value to IQAI than waste it over here trying to knock FDBK?

[ducatiman] 04/7/2023 08:10

Clever indeed and along with Oakley, Patel and a number of other members of the venerable team, smart enough to not be shareholders.

[lr2] 03/7/2023 17:47

Obviously suffering from old man syndrome, I'll stop posting for awhile.

[petekand] 03/7/2023 16:55

In all that excitement, I think you forgot you had already posted this drivel last week.
Yes, he is very smart to have held down the job for so long without any result.

[lr2] 03/7/2023 10:43

One smart cookie IMHO.

[ducatiman] 30/6/2023 19:40

Another week of diminishing returns for shareholders.
I wonder if the executives salaries have diminished?
What will TO get a bonus for this year?



Walter Mitty!?

[lr2] 26/6/2023 20:21

Hey Duc, Antoine Saillant is the brains behind Bleepa / CareLocker as far as I can tell. He's probably well worth the salary he gets compared to others employed at Feedback plc.

He worked for Siemens Healthineers for almost 5 years before joining Feedback plc. Pretty sure he is one smart cookie.

[ducatiman] 26/6/2023 17:46

LR2, another nice title “head of product”! 4 years salary =£?
FybberF, I cling to the hope that Prof Shaw’s substantial on market buying was done with some idea that the potential will be delivered at some stage. However as a businessman I am appalled at the waste here.

[lr2] 26/6/2023 16:53

We sat down with our Head of Product Antoine Saillant to discuss the evolution of Bleepa and developing of a complex, regulated digital product that meets real-world medical needs. Read the full article here 👉

[ydderf] 26/6/2023 16:41

ducatiman - serious question, why don't you sell? The psychological cost must be great cumulatively over the years? Take a load off?

[digger2779] 26/6/2023 16:03

Just had a look at our financials on ADVFN and they haven't caught up with our 200 for 1 consolidation as we are showing a market cap of 2.87 billion!! If only, or maybe wonderboy isn't telling us something.

[ducatiman] 20/6/2023 16:33

So my uptake of the trading update was summised above. More bullsh1t.
Maybe it’s just me but this is how it was translated by another party, lol.

Feedback expects annual revenue boost; "exciting" opportunities ahead

[ducatiman] 20/6/2023 16:28

Have to hold fybberF to account here. He obviously didn’t read the update and obviously hasn’t followed Bleepa’s progress over the last three years.from the update:-

Bleepa v1.5 incorporates a number of advanced features that further strengthen the proposition including:

-- the ability to share the patient record to a clinician outside of the current hospital deployment, opening the potential for truly regional or national care delivery;

-- enhanced features for document capture such as document preview and categorisation enabling users to contribute to the patient record with virtually any medical information (referral letter, ECG trace, blood report, etc); and

-- improved messaging functionalities such as tagging teams and individuals and making structured notes to enable users to communicate even more intuitively, quickly and safely.

[ydderf] 19/6/2023 20:04

Ockham's Razor surely, the most likely explanation for no commercial interest is nobody's interested? TO has had years to prove otherwise. Another problem never discussed here is that much has changed in the last three or four years including advances in AI but as far as I can ascertain Bleepa is the same as three years ago...

[ducatiman] 19/6/2023 18:37

He could be correct but is anyone listening?
His last shot?

[lr2] 19/6/2023 14:00

Dr Thomas Oakley’s Post

I am pleased to share the news that I will be speaking at the All Party Parliamentary Group (APPG) for Diagnostics on Wednesday alongside Sir Mike Richards, Rhydian Phillips, Alexandra Pinches, Dr Katharine Halliday and Professor Michael Osborn. We will be addressing the challenges facing the CDC rollout and I will be advocating for the role of digital tools as the third pillar of core infrastructure, alongside investments in bricks & mortar and staffing. The NHS has made significant investment in the latter two but there is now a gaping hole in the digital elements of the CDC programme.

In 2021 I advocated that CDCs represented a once in a generation opportunity to fix our digital infrastructure - without the right digital foundations we will not unlock the full potential of the CDC programme to impact wait times.

We have now shown the impact of Bleepa on the CDC programme, having demonstrated a 70% reduction in patient wait times, without the need for additional clinical staff, all whilst generating a huge cash saving for the system.

I will be putting the case for national focus on digital commissioning to MPs during the APPG and will be pleased to represent wider industry suppliers, especially SMEs. If there is something that you would like me to take to the discussion then please DM me.

With winter pressures bearing down upon us the reality is that most physical builds will not deliver in time and staffing solutions are even further out. Only digital tools, adopted at pace across the system, can impact waiting lists and diagnostic workflows in time.

These solutions are here, but we need honest and robust conversations about commissioning them centrally and the decisions need to be made now on behalf of the system, regional commissioning is too slow to meet the needs of patients, both now and ahead of winter.

[ydderf] 19/6/2023 12:02

yump do you think that if they had an order they would not find 3 different ways to tell us and of course it would be included in a trading update, the term is not defined in the way you suggest. They have no need to sell stuff when they can raise a few more million every year or two. Shareholders get the management the deserve (think about it) most original shareholders have dumped and run over past years - why is that?